A comparison of the efficiacy of new asymmetric bispyridinium oximes (K027, K048) with currently available oximes against tabun by in vivo methods

Abstract

The potency of newly developed asymmetric bispyridinium oximes (K027, K048) in reactivating tabun-inhibited acetylcholinesterase and in eliminating tabun-induced toxic effects was compared with commonly used oximes (obidoxime, trimedoxime, the oxime HI-6)